Advertisement

Covidien plc (NYSE: COV) CEO José (Joe) E. Almeida said Thursday that the life sciences company is likely to add workers outside the United States, as a growing portion of the company’s revenues come from international sales.

“We need to do more with the right people in the right places,” Almeida said at a gathering of medical device executives in Boston Thursday, when asked about the jobs impact of restructuring plans announced last week as part of the company’s earnings release. The restructuring, which will include unspecified layoffs, is expected to save Covidien between $175 million and $225 million per year, by 2014.

SOURCE

Advertisement
Advertisement